CD276 and melanoma: The efficacy of the first anti-B7-H3 therapeutic mAb (Enoblituzumab) against B7-H3 expressing tumors, including melanoma, is under examination, alone or in combination with other ICIs, in Phase I-II human clinical trials (71) (https://clinicaltrials.gov/ct2/show/NCT02475213).